应对青光眼中的神经退行性变:机制、挑战与治疗
青光眼是全球不可逆盲的首要病因,视网膜神经节细胞(RGC)投射至脑的神经退行性变导致视力丧失。降眼压是主要治疗但部分患者仍持续丧失视力,针对不依赖眼压的神经保护或修复治疗(生长因子、代谢靶向化合物、抗炎抗氧化剂、神经调质)在临床转化中面临挑战。作者提出先在多种动物模型(包括非人灵长类)中充分评估靶点、并倡导联合治疗以提高神经保护治疗成功率。
要点
- 青光眼视力丧失源于RGC投射至脑的神经退行性变,主要治疗为降眼压但许多患者仍持续丧失视力。
- 针对不依赖眼压的神经保护或修复治疗包括生长因子、代谢靶向化合物、抗炎抗氧化剂和神经调质。
- 作者提出临床前应在多种动物模型(包括非人灵长类)中充分评估靶点,并倡导联合治疗。
核心结论
- 作者提出两条策略以提高青光眼神经保护治疗的成功率:一是在临床试验前于多种动物模型(包括非人灵长类)中充分评估实验靶点,二是倡导联合治疗(同时使用多种药物),尤其在疾病早期和潜在可逆阶段。
研究设计与样本
- 本文为综述,围绕青光眼神经退行性变的机制、挑战与治疗进行论述,未报告系统检索范围。
主要发现
- 青光眼因视网膜神经节细胞(RGC)投射至脑的神经退行性变导致视力丧失,并与眼压敏感相关。
- 许多针对不依赖眼压的神经保护或修复治疗(生长因子、代谢靶向化合物、抗炎抗氧化剂、神经调质)在实验模型中成功,但未能转化为临床获益。
- 转化困难的因素包括:视神经乳头的解剖结构在啮齿类、非人灵长类与人类之间存在差异;动物模型不能复制人类复杂的青光眼病理生理。
关键数值与推荐
- 原文未报告具体数值标准或推荐等级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出视神经乳头的解剖结构在啮齿类、非人灵长类与人类之间存在差异。
- 原文指出动物模型不能复制人类复杂的青光眼病理生理。
- 原文指出许多神经保护或修复治疗在实验模型中成功但未能转化为临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glaucoma is the leading cause of irreversible blindness globally. The disease causes vision loss due to neurodegeneration of the retinal ganglion cell (RGC) projection to the brain through the optic nerve. Glaucoma is associated with sensitivity to intraocular pressure (IOP). Thus, mainstay treatments seek to manage IOP, though many patients continue to lose vision. To address neurodegeneration directly, numerous preclinical studies seek to develop protective or reparative therapies that act independently of IOP. These include growth factors, compounds targeting metabolism, anti-inflammatory and antioxidant agents, and neuromodulators. Despite success in experimental models, many of these approaches fail to translate into clinical benefits. Several factors contribute to this challenge. Firstly, the anatomic structure of the optic nerve head differs between rodents, nonhuman primates, and humans. Additionally, animal models do not replicate the complex glaucoma pathophysiology in humans. Therefore, to enhance the success of translating these findings, we propose two approaches. First, thorough evaluation of experimental targets in multiple animal models, including nonhuman primates, should precede clinical trials. Second, we advocate for combination therapy, which involves using multiple agents simultaneously, especially in the early and potentially reversible stages of the disease. These strategies aim to increase the chances of successful neuroprotective treatment for glaucoma.
引用
- Bou Ghanem GO, Wareham LK, Calkins DJ, et al. Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments. Prog Retin Eye Res. 2024. PMID: 38527623. doi:10.1016/j.preteyeres.2024.101261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。